Bio-Rad Laboratories, Inc. engages in the development and production of specialty chemicals used in biochemical, pharmaceutical, and other life science research applications. The company manufactures and supplies the life science research, healthcare, analytical chemistry, and other markets with a range of products and systems used to separate complex chemical and biological materials and to identify, analyze, and purify their components. It has direct distribution channels in approximately 35 countries outside the United States through subsidiaries whose focus is sales, customer service, and product distribution. In some regions, sales efforts are supplemented by distributors and agents. Segments The company operates in two segments, Life Science and Clinical Diagnostics. Life Science This segment engages in the discovery and creation of advanced tools to answer complex biological questions. The company develops, manufactures, and markets a range of approximately 5,000 reagents, apparatus, and laboratory instruments that serve a global customer base. Majority of its products are used in established research techniques, biopharmaceutical production processes, and food testing regimes. These techniques are used to separate, purify, and identify biological materials, such as proteins, nucleic acids, and bacteria within a laboratory or production setting. The company focuses on selected segments of the life sciences market in proteomics (the study of proteins), genomics (the study of genes), biopharmaceutical production, cell biology, and food safety. The company’s principal life science customers include universities and medical schools, industrial research organizations, government agencies, pharmaceutical manufacturers, biotechnology researchers, food producers, and food testing laboratories. Clinical Diagnostics This segment designs, manufactures, sells, and supports test systems, informatics systems, test kits, and specialized quality controls that serve clinical laboratories in the global diagnostics market. The company’s products address specific niches within the in vitro diagnostics (IVD) test market. The company supplies approximately 3,000 different products that cover approximately 300 clinical diagnostic tests to the IVD test market. IVD tests are conducted outside the human body and are used to identify and measure substances in a patient’s tissue, blood or urine. The company’s products consist of reagents, instruments, and software, provided to its customers as an integrated package to allow them to generate reproducible test results. The company’s principal clinical diagnostic customers include hospital laboratories, reference laboratories, transfusion laboratories, and physician office laboratories. Sales and Marketing The company conducts its worldwide operations through a direct sales force and service network. Its worldwide customer base includes prominent university and research institutions, providing the company access to approximately 150,000 scientists in the United States alone; hospital, public health and commercial laboratories; other major diagnostic manufacturers; and primary companies in the biotechnology, pharmaceutical, chemical and food industries. Research and Development The company spent approximately $220.3 million on research and development activities in 2014. Regulatory Matters The development, testing, manufacturing, marketing, post-market surveillance, distribution, advertising and labeling of certain of the company’s products (primarily diagnostic products) are subject to regulation in the United States by the Center for Devices and Radiological Health of the U.S. Food and Drug Administration and in other jurisdictions by state and foreign government authorities. Competition Life Science: This segment’s competitors include GE Biosciences, Merck Millipore, and Thermo Fisher Scientific. Clinical Diagnostics: This segment’s major competitors include Roche, Abbott Laboratories, Siemens, Danaher, Thermo Fisher, Becton Dickinson, bioMerieux, Ortho Clinical Diagnostics, Tosoh, Immucor, and DiaSorin. History Bio-Rad Laboratories, Inc. was founded in 1952. The company incorporated in 1957.
(BIO:New York Consolidated)
1000 Alfred Nobel Drive
Hercules, CA 94547
|Alere Inc||$52.91 USD||+2.82|
|DiaSorin SpA||€43.29 EUR||+0.87|
|IDEXX Laboratories Inc||$74.11 USD||-0.065|
|QIAGEN NV||€25.85 EUR||+0.145|
|View Industry Companies|
Sponsored Financial Commentaries
To contact BIO-RAD LABORATORIES-A, please visit www.bio-rad.com. Company data is provided by Capital IQ. Please use this form to report any data issues.